ResearchMoz

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

GBI Research
Published Date » 2014-03-07
No. Of Pages » 109
   
 GBI Research, the leading business intelligence provider, has released its latest research: ‘NSCLC Therapeutics in APAC Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool’, which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8...
Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Symptoms 10
2.2 Etiology 11
2.3 Pathophysiology 12
2.4 Co-morbidities and Complications 12
2.5 Diagnosis 13
2.5.1 Physical Examination 13
2.5.2 Sputum Cytology 13
2.5.3 Imaging Tests 13
2.5.4 Biopsy 14
2.6 Classification 15
2.6.1 Adenocarcinoma 15
2.6.2 Squamous Cell Carcinoma 15
2.6.3 Large Cell Carcinoma 15
2.7 Epidemiology 15
2.8 Prognosis and Disease Staging 16
2.8.1 Staging 16
2.9 Treatment Options 18
2.9.1 Surgery and Radiation Therapy 18
2.9.2 Pharmacological 18
2.9.3 Treatment Algorithms and Prescribing Habits 20

3 Marketed Products 23
3.1 Therapeutic Landscape 24
3.1.1 Alimta (pemetrexed disodium) – Eli Lilly and Company 24
3.1.2 Abraxane (nab-paclitaxel) – Celgene 26
3.1.3 Iressa (gefitinib) – AstraZeneca 28
3.1.4 Tarceva (erlotinib hydrochloride) – F. Hoffmann-La Roche 29
3.1.5 Xalkori (crizotinib) – Pfizer 31
3.1.6 Avastin (bevacizumab) – F. Hoffmann-La Roche 32
3.1.7 Gilotrif (afatinib) – Boehringer Ingelheim 34
3.2 Comparative Efficacy and Safety 34

4 Pipeline Products 37
4.1 Overall Pipeline 37
4.2 Pipeline Analysis by Molecule Type 39
4.3 Pipeline Analysis by Mechanism of Action 41
4.4 Clinical Trials 44
4.4.1 Failure Rate 44
4.4.2 Patient Enrollment and Clinical Trial Size 46
4.4.3 Duration 48
4.5 Promising Drug Candidates in the Pipeline 50
4.5.1 Ramucirumab (IMC-1121B) – Eli Lilly and Company 50
4.5.2 Necitumumab (IMC-11F8) – Eli Lilly and Company 50
4.5.3 Onartuzumab (MetMab) – F. Hoffmann-La Roche 51
4.5.4 Ganetespib (STA-9090) – Synta 52
4.5.5 Nintedanib (BIBF1120) – Boehringer Ingelheim 52
4.5.6 Dacomitinib (PF-00299804) – Pfizer 53
4.5.7 LDK378 – Novartis 54
4.5.8 Yervoy (ipilimumab) – Bristol-Myers Squibb 54
4.5.9 Nivolumab (BMS-936558/ONO-4538) – Bristol Myers Squibb 55

5 Market Forecast to 2019 56
5.1 Geographical Markets 56
5.1.1 APAC Market 56
5.1.2 India 57
5.1.3 Australia 60
5.1.4 China 62
5.1.5 Japan 64
5.2 Drivers and Barriers for the Disease Market 66
5.2.1 Drivers 66
5.2.2 Barriers 66

6 Deals and Strategic Consolidations 68
6.1 Major Co-development Deals 69
6.1.1 OxOnc Enters Co-development Agreement with Pfizer for Crizotinib 70
6.1.2 SFJ Pharma Enters Co-development Agreement with Pfizer for Dacomitinib 70
6.1.3 Merck Enters Co-development Agreement with Endocyte for Cancer Drug 71
6.1.4 Roche Enters Co-development Agreement with Clovis 71
6.1.5 Abbott Laboratories Enters Co-development Agreement with GlaxoSmithKline 71
6.2 Major Licensing Deals 71
6.2.1 Chugai Enters Licensing Agreement with Roche for Onartuzumab and Lebrikizumab 72
6.2.2 Azaya Enters Licensing Agreement with CANbridge Life Sciences for ATI-1123 73
6.2.3 Merck Expands Licensing Agreement with Biomira 73
6.2.4 Clovis Enters Licensing Agreement with Avila Therapeutics 73

7 Appendix 74
7.1 All Pipeline Drugs by Phase 74
7.1.1 Discovery 74
7.1.2 Preclinical 75
7.1.3 IND-filed 78
7.1.4 Phase I 78
7.1.5 Phase II 82
7.1.6 Phase III 86
7.1.7 Undisclosed 89
7.2 Market Forecasts to 2019 97
7.2.1 APAC 97
7.2.2 India 98
7.2.3 Australia 98
7.2.4 China 98
7.2.5 Japan 99
7.3 Market Definitions 99
7.4 Abbreviations 99
7.5 Bibliography 102
7.6 Research Methodology 105
7.6.1 Coverage 105
7.6.2 Secondary Research 106
7.6.3 Primary Research 106
7.6.4 Therapeutic Landscape 106
7.6.5 Geographical Landscape 108
7.6.6 Pipeline Analysis 109
7.7 Expert Panel Validation 109
7.8 Contact Us 109
7.9 Disclaimer 109

List of Tables

Table 1: Non-Small Cell Lung Cancer Market, Common Symptoms of Non-Small Cell Lung Cancer 11
Table 2: Non-Small Cell Lung Cancer Market, Risk Factors of Non-Small Cell Lung Cancer Market 12
Table 3: Non-Small Cell Lung Cancer Market, American Joint Committee on Cancer’s Tumor Node Metastasis Staging System, 2010 17
Table 4: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Discovery), 2013 74
Table 5: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 75
Table 6: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (IND-filed), 2013 78
Table 7: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase I), 2013 78
Table 8: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase II), 2013 82
Table 9: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase III), 2013 86
Table 10: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013 89
Table 11: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Forecast, 2012–2019 97
Table 12: Non-Small Cell Lung Cancer Market, India, Market Forecast, 2012–2019 98
Table 13: Non-Small Cell Lung Cancer Market, Australia, Market Forecast, 2012–2019 98
Table 14: Non-Small Cell Lung Cancer Market, China, Market Forecast, 2012–2019 98
Table 15: Non-Small Cell Lung Cancer Market, Japan, Market Forecast, 2012–2019 99

List of Figures

Figure 1: Non-Small Cell Lung Cancer Market, Asia-Pacific, Distribution of Prevalence Population, 2012–2019 16
Figure 2: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 20
Figure 3: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 21
Figure 4: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Advanced Metastatic Tumors, 2013 22
Figure 5: Non-Small Cell Lung Cancer Market, Global, Annual Sales, 2012 24
Figure 6: Non-Small Cell Lung Cancer Market, Global, Alimta (pemetrexed disodium) Annual Sales ($bn), 2004–2012 25
Figure 7: Non-Small Cell Lung Cancer Market, Global, Abraxane (nab-paclitaxel) Annual Sales ($m), 2009–2012 27
Figure 8: Non-Small Cell Lung Cancer Market, Global, Iressa (gefitinib) Annual Sales ($m), 2005–2012 28
Figure 9: Non-Small Cell Lung Cancer Market, Global, Tarceva (erlotinib) Annual Sales ($bn), 2006–2012 30
Figure 10: Non-Small Cell Lung Cancer Market, Global, Xalkori (crizotinib) Annual Sales ($m), 2012–2013 31
Figure 11: Non-Small Cell Lung Cancer Market, Global, Avastin (bevacizumab) Annual Sales ($bn), 2006–2012 33
Figure 12: Non-Small Cell Lung Cancer Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 35
Figure 13: Non-Small Cell Lung Cancer Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2013 38
Figure 14: Non-Small Cell Lung Cancer Market, Global, Pipeline by Molecule Type and Stage of Development, 2013 40
Figure 15: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, 2013 42
Figure 16: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2013 43
Figure 17: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Failure Rate (%), 2013 45
Figure 18: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Size (Participants), 2013 47
Figure 19: Non-Small Cell Lung Cancer Market, Global, Pipeline Clinical Trial Duration (months), 2013 49
Figure 20: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Size, 2012–2019 57
Figure 21: Non-Small Cell Lung Cancer Market, India, Market Size, 2012–2019 59
Figure 22: Non-Small Cell Lung Cancer Market, Australia, Market Size, 2012–2019 61
Figure 23: Non-Small Cell Lung Cancer Market, China, Market Size, 2012–2019 63
Figure 24: Non-Small Cell Lung Cancer Market, Japan, Market Size, 2012–2019 65
Figure 25: Non-Small Cell Lung Cancer Market, Global Deals by Value, Year and Stage of Development, 2006–2013 68
Figure 26: Non-Small Cell Lung Cancer Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006–2013 69
Figure 27: Non-Small Cell Lung Cancer Market, Global, Co-development Deals by Geography, 2006–2013 70
Figure 28: Non-Small Cell Lung Cancer Market, Global, Licensing Deals by Geography, 2006–2013 72
Figure 29: GBI Research Market Forecasting Model (Example) 108

Upcoming Reports:

Omega 3 And 6 Market - Global Industry size, market share, trends, analysis and forecasts 2012 - 2018
By - Transparency Market Research
Omega 3 and omega 6 are the essential fatty acids which are not synthesized by the body but are important for its metabolism. Marine oils, one of the sources of omega 3, continue to dominate the omega 3 fatty acids market. Fish oil concentrates are expected to witness highest growth in terms of volume as well as value in upcoming years.  The market for omega 3 and omega 6 is expected to witness considerable growth in the near future due to increasing market potential and growing preference from consumers. This market is expected to continue penetrating functional...
FAME (Fatty Acid Methyl Esters) - Global Industry Analysis, Market Share, Size, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Fatty acid methyl esters (FAME) are produced by reacting fatty acids and methanol. They are also present in biodiesels and are similar to those in conventional diesel but expel lower concentrations of toxic emissions and thus, are non-toxic and biodegradable. They are produced from vegetable oils and animal fats by the process of transesterification. Rapeseed, soybean, UCO, palm oils, sunflower and animal fat are used as raw materials for the production of FAME. FAME have high oxidation stability and hence can be used under normal conditions. The use of these esters...
Hospital Asset Management Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
A hospital asset management solution helps in managing and maintaining the various equipments located throughout the hospital campus by a set of automation and optimization processes. Based on technology, the hospital asset management market can be segmented into four categories, namely, radio-frequency identification (RFID), Wi-Fi based real-time location systems (RTLS), ultrasound and infrared. The healthcare industry utilizes all four technologies, while the pharmaceuticals segment utilizes only the RFID technology. The healthcare asset management market includes patient...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

US Vessel Cape Ray Destroyed Syrias Chemical Weapons
Aug 19, 2014  
RIA Novosti, Monday news stated that teams aboard the MV Cape Ray (US vessel) have completed the task of neutralizing the chemical stockpile materials declared in Syria. This was informed by John Kirby, Pentagon Press Secretary Rear Adm. The Secretary of Defense – Chuck Hagel congratulated the Navy Captain – Rich Dromerhauser ship's crew on completing their task of...
Surge in Bourbon Production
Aug 19, 2014  
America’s bourbon whiskey manufacturer, Kentucky, has taken a decision on hoarding large stockpiles of bourbon whiskey. According to sources, distillers are stocking up the huge quantities of bourbon even before the demand for the same has arisen in the market.  This step of excess production involves a certain risk, but as soon as the market demand for this dominates the...
Decline in China Home Prices Reach Third Straight Month
Aug 18, 2014  
Recently, a trend of fall in Chinese home prices has been noted. This decline has occurred for its third straight month. During July, the prices of housing eased from June, but third straight monthly fall was noted. The prices were still up by 2.5 pc on year, however slowest gain was noted in 17 months. A fall of new home prices in 64 cities in June was displayed versus the 55 figure...
WHO Urges Countries to Avoid Blanket Ban with Ebola-affected Countries
Aug 18, 2014  
The World Health Organization has requested governments to not sever ties with Ebola-affected states completely. The request comes after Kenya refused to carry on any form of trade or travel with the three West African states suffering from the deadly disease. The international health organization has already stated that risk of Ebola transmission via air travel is minimal. However, it...
Amines Capacity Expansion in Brazil by Clariant
Aug 18, 2014  
In order to meet the increasing demand of the mining industry, Clariant, which is a Switzerland-based specialty company dealing in chemicals, aims at doubling its production capacity of ether amines. The increase in productive capacity pertains to its Suzano facility in Brazil. The expansion of the production capacity will not only cater to the rising customer demand for ether amines in Brazil...